Prevalence and clinical significance of RBM3 immunostaining in non-small cell lung cancers.
Immunohistochemistry
Large cell lung carcinoma
Lung adenocarcinoma
Non-small-cell lung carcinoma
RBM3
Squamous cell lung carcinoma
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
received:
25
09
2018
accepted:
23
01
2019
pubmed:
14
2
2019
medline:
16
4
2019
entrez:
14
2
2019
Statut:
ppublish
Résumé
Aberrant expression of RNA-binding motif protein 3 (RBM3) has been suggested as a prognostic biomarker in several malignancies. This study was performed to analyse the prevalence and clinical significance of RBM3 immunostaining in non-small cell lung cancers (NSCLCs). Therefore, we took advantage of our tissue microarray (TMA) containing more than 600 NSCLC specimens. While nuclear RBM3 staining was always high in normal lung tissue, high RBM3 staining was only seen in 77.1% of 467 interpretable non-metastatic NSCLCs. Reduced RBM3 staining was significantly associated with advanced pathological tumor stage (pT) in NSCLCs (p = 0.0031). Subset analysis revealed that the association between reduced RBM3 staining and advanced pT stage was largely driven by the histological subgroup of lung adenocarcinoma (LUACs) (p = 0.0036). In addition, reduced RBM3 expression predicted shortened survival in LUAC patients (p = 0.0225). In summary, our study shows that loss of RBM3 expression predicts worse clinical outcome in LUAC patients.
Identifiants
pubmed: 30758670
doi: 10.1007/s00432-019-02850-1
pii: 10.1007/s00432-019-02850-1
doi:
Substances chimiques
Biomarkers, Tumor
0
RBM3 protein, human
0
RNA-Binding Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
873-879Références
J Biol Chem. 2001 Nov 2;276(44):40680-6
pubmed: 11546759
Hum Mol Genet. 2002 Sep 15;11(19):2279-87
pubmed: 12217956
J Cell Sci. 2004 Apr 1;117(Pt 9):1785-94
pubmed: 15075239
J Cell Biochem. 2006 Apr 15;97(6):1275-82
pubmed: 16552754
Oncogene. 2008 Jul 31;27(33):4544-56
pubmed: 18427544
J Cell Biochem. 2009 May 1;107(1):179-88
pubmed: 19277990
RNA. 2009 Jun;15(6):1164-76
pubmed: 19398494
Mod Pathol. 2009 Dec;22(12):1564-74
pubmed: 19734850
Pediatr Res. 2010 Jan;67(1):35-41
pubmed: 19770690
Biochim Biophys Acta. 2010 Jan;1805(1):43-52
pubmed: 19900510
Methods Mol Biol. 2010;664:37-44
pubmed: 20690050
J Transl Med. 2010 Aug 20;8:78
pubmed: 20727170
J Transl Med. 2011 Jul 21;9:114
pubmed: 21777469
Transl Oncol. 2011 Aug;4(4):212-21
pubmed: 21804916
Diagn Pathol. 2011 Sep 28;6:91
pubmed: 21955582
Proteomics Clin Appl. 2011 Dec;5(11-12):624-35
pubmed: 21956899
Diagn Pathol. 2012 Jul 17;7:82
pubmed: 22805320
BMC Urol. 2013 Apr 08;13:17
pubmed: 23565664
Chin Med J (Engl). 2013;126(10):1948-52
pubmed: 23673116
Eur J Cancer. 2014 Mar;50(4):852-61
pubmed: 24380696
Biomark Res. 2014 Jun 17;2:11
pubmed: 24963396
Biochim Biophys Acta. 2015 Jul;1849(7):881-6
pubmed: 25316157
PLoS One. 2015 Mar 26;10(3):e0121300
pubmed: 25811459
Histopathology. 2016 Jan;68(2):191-8
pubmed: 25922889
Oncotarget. 2017 Mar 28;8(13):22235-22250
pubmed: 28118608
Hum Mol Genet. 1995 Dec;4(12):2307-11
pubmed: 8634703